ProMIS Neurosciences Inc Dossier - Source-backed chat

ProMIS Neurosciences Inc

PMNNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $9.38Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $84.1M

Enterprise Value $78M

Shares Outstanding 9M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

ProMIS Neurosciences is a clinical-stage biotechnology company uniquely positioned to address the massive unmet need in Alzheimer's disease (AD) through its lead candidate, PMN310. Unlike currently approved monoclonal antibodies (such as Leqembi and Kisunla) that target amyloid plaques and carry black-box warnings for Amyloid-Related Imaging Abnormalities (ARIA), PMN310 is rationally designed to selectively target toxic soluble amyloid-beta oligomers while avoiding plaque binding. This mechanism of action aims to deliver comparable or superior efficacy with a significantly improved safety profile. Backed by a transformational private placement (PIPE) of up to $175 million closed in early 2026, the company has secured its financial runway through 2027, fully funding the ongoing PRECISE-AD Phase 1b trial. Near-term catalysts, including a blinded 6-month interim safety and biomarker readout in early Q3 2026, represent major inflection points that could validate ProMIS's proprietary EpiSelect™ platform and re-rate the stock.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$18.23

Mean target$43.94

High · most bullish analyst$100.47

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.0020%

The blinded interim analysis or subsequent top-line data reveals unexpected safety concerns, such as high rates of ARIA, or fails to show meaningful biomarker changes. This lack of differentiation from existing therapies severely damages the clinical thesis of PMN310. Consequently, the company struggles to attract partners or raise additional capital, leading to severe shareholder dilution or a halt in development.

Base CaseCentral scenario

$26.5050%

The Phase 1b trial progresses on schedule with a favorable safety profile and no treatment-related serious adverse events. The blinded interim analysis in early Q3 2026 confirms aggregate safety and positive biomarker trends, maintaining investor enthusiasm. The company completes 12-month dosing by year-end and remains on track to report unblinded top-line results in early 2027, supported by its cash runway through 2027.

Bull CaseUpside scenario

$35.0030%

The PRECISE-AD Phase 1b trial demonstrates a near-zero incidence of ARIA and strong directional biomarker engagement in the early Q3 2026 interim analysis. This clinical validation triggers a lucrative co-development partnership with a major pharmaceutical company, providing non-dilutive funding and accelerating the transition directly into a single registrational study. PMN310 is recognized as a best-in-class, safer alternative to plaque-binding therapies, driving the stock toward the high end of analyst targets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated Mechanism of Action: PMN310 selectively targets toxic soluble amyloid-beta oligomers, avoiding plaque and monomer binding to minimize ARIA risk.
Strong Financial Runway: The early 2026 PIPE financing of up to $175 million extends the company's operational runway through 2027, covering key clinical readouts.
Fast Track Designation: PMN310 received FDA Fast Track designation in July 2025, facilitating closer regulatory engagement and potentially accelerating the approval pathway.

Key Investment Risks

Binary Clinical Trial Risk: The company's valuation is heavily dependent on the clinical success of a single asset, PMN310, in early-stage trials.
Intense Competitive Landscape: Large pharmaceutical companies (e.g., Eli Lilly, Biogen/Eisai) have already commercialized AD therapies, establishing a high bar for market entry.
Future Dilution Risk: Despite the current cash runway, advancing PMN310 into large-scale registrational trials will require substantial capital, posing long-term dilution risks.

Thesis Invalidation Triggers

Observation of significant or unexpected ARIA cases in the PRECISE-AD Phase 1b trial.
Failure to demonstrate directional biomarker engagement or target engagement in the upcoming clinical readouts.
Inability to advance the subcutaneous formulation of PMN310 or secure regulatory clearance for a registrational study.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.